Projects per year
Project Details
Description
The genetic lesions that promote tumorigenesis, including chromosomal rearrangements, are generated
primarily by illegitimate DNA repair. In this renewal application, we will continue to investigate the pathological
consequences of aberrant DNA double-strand break (DSB) repair. This highly collaborative and integrated
program will elucidate how DNA sequence, chromatin accessibility and nuclear organization influence the fate
and pathological outcomes of DSBs in a cell type and cell cycle dependent manner. We will continue to use a
combination of genetics in yeast and mouse models, biochemistry and cell biology. The application of next
generation technologies together with high-throughput genomics approaches provides an unprecedented wealth
of information about genomic instability in cancer genomes. We propose to leverage our multifaceted
experimental approach with the strong genomics and computational biology components that pervade the
Program. Drs. Rabadan and Baer will study mutation signatures - the statistically enriched patterns of DNA
substitutions and rearrangements common across tumors - associated with specific BRCA1 deficiencies. They
will also characterize mutation signatures generated by the other three Projects. Collectively these data will help
deconvolute the complex mutational landscape of human tumors. Drs. Symington and Ciccia will address the
nature of the initiating DNA lesions resulting in chromosome rearrangements, focusing on DNA replication errors
in repair-deficient yeast and genome-edited mammalian cells. Dr. Sha will connect chromatin accessibility, locally
and globally, with its propensity to break and yield translocations; pathological translocations at the
immunoglobulin and T cell receptor loci during lymphocyte maturation fuel lymphoma development. Specifically,
Dr. Zha will elucidate how ATM deficiencies favor translocations in a cell type and cell cycle dependent manner.
Finally, Drs. Gautier and Gottesman will study how the spatial organization of the nucleus modulates DNA repair.
Specifically, they will determine how nuclear actin and WASP, the gene mutated in Wiskott-Aldrich Syndrome,
enables resection and influences chromosome translocations following DSBs or genotoxic lesions triggered by
topoisomerase inhibition. The four Projects will be supported by two scientific Cores. All leaders and co-leaders
have a strong history and record of productive collaboration.
Status | Finished |
---|---|
Effective start/end date | 4/8/14 → 3/31/23 |
Funding
- National Cancer Institute: US$12,458,408.00
- National Cancer Institute: US$1,778,566.00
- National Cancer Institute: US$1,778,566.00
- National Cancer Institute: US$1,782,789.00
ASJC Scopus Subject Areas
- Cancer Research
- Genetics
- Molecular Biology
- Oncology
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.
Projects
- 14 Finished